Farabi Pharmaceutical (XTEH:DFRB1) EBIT: IRR Mil (TTM As of . 20)


What is Farabi Pharmaceutical EBIT?

Farabi Pharmaceutical XTEH:DFRB1 EBIT is IRR Mil as of . 20.

Farabi Pharmaceutical's earnings before interest and taxes (EBIT) for the three months ended in . 20 was IRR0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Farabi Pharmaceutical  (XTEH:DFRB1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Farabi Pharmaceutical's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is four times the quarterly (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Farabi Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Farabi Pharmaceutical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical EBIT Related Terms

Farabi Pharmaceutical EBIT Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical EBIT Chart

Farabi Pharmaceutical Annual Data
Trend
EBIT

Farabi Pharmaceutical Quarterly Data
EBIT

XTEH:DFRB1 vs IMNPQ, INNV: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farabi Pharmaceutical EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Farabi Pharmaceutical's EV-to-EBIT falls into.


Farabi Pharmaceutical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was IRR Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of IRR Mil mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a EBIT of IRR Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Farabi Pharmaceutical.
Is Farabi Pharmaceutical's EBIT too high?
Farabi Pharmaceutical's current EBIT is IRR Mil.
How does Farabi Pharmaceutical's EBIT compare to IMNPQ and INNV?
Farabi Pharmaceutical's EBIT of IRR Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Farabi Pharmaceutical. Farabi Pharmaceutical's current EBIT is IRR Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current EBIT of IRR Mil. The current EBIT is IRR Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current EBIT is IRR Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.